Praxis Precision Medicines, Inc. Common Stock
Symbol: PRAX (NASDAQ)
51.00
▼ (-3.77%) -1.999
Company Description:
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Key Stats
- Today's Open: $52.74
- Today's High: $54.245
- Today's Low: $51.001
- Today's Volume: 322.87K
- Yesterday Close: $53
- Yesterday High: $55.33
- Yesterday Low: $51.03
- Yesterday Volume: 652.60K
- Last Min Volume: 0
- Last Min High: $51.004
- Last Min Low: $51.001
- Last Min VWAP: $0
Company Profile
- Name: Praxis Precision Medicines, Inc. Common Stock
- Website: https://www.praxismedicines.com
- Listed Date: 2020-10-16
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001689548
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.12B
- Round Lot: 100
- Outstanding Shares: 21.05M
- Asset Type: CS
RECENT FILINGS FOR PRAX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-25 | 4 | View |
| 2025-09-05 | 8-K | View |
| 2025-09-05 | 424B5 | View |
| 2025-09-02 | SCHEDULE 13G/A | View |
| 2025-08-19 | 3 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-08-04 | 8-K | View |
| 2025-08-04 | 10-Q | View |
| 2025-07-22 | SCHEDULE 13G | View |
| 2025-07-17 | 8-K | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
Latest News on PRAX